相关实验视频

Updated: May 3, 2026

An Acupoint Catgut-embedding Therapy for Treating Obesity

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

在肥胖妇女中肥胖和甲状腺功能:试点研究

C Jemai¹, R Gharbi², H Kandara²

¹1Faculty of Medicine of Tunis; 2National Institute of Nutrition of Tunis, Department C, Tunisia.

Georgian medical news

|March 30, 2025

概括

这项针对肥胖女性的研究发现,自由甲状腺素 (FT4) 水平,而不是甲状腺刺激激素 (TSH),与心脏代谢风险因素相关. 这些发现突出了FT4的特点.

科学领域:

内分泌学在内分泌学.
代谢健康代谢健康
肥胖问题研究研究

背景情况:

肥胖是一个日益严重的全球健康问题,特别是在突尼斯.
甲状腺功能障碍在肥胖个体中很常见.
了解甲状腺状况与肥胖的代谢健康之间的关系至关重要.

研究的目的:

在一群肥胖的突尼斯妇女中评估甲状腺功能.
研究甲状腺状况参数 (FT4,TSH) 与临床/代谢因素之间的关联.
探索与身体组成,胰岛素抵抗和脂质样本的相关性.

主要方法:

对50名肥胖女性进行横截面回顾性研究.
收集的数据包括身体质量指数 (BMI),腰围 (WC),禁食血糖,胰岛素,脂质概况和通过生物电阻测量的身体组成.
针对胰岛素耐药性 (HOMA-IR) 和β细胞功能 (HOMA-B) 的计算恒温模式评估.

主要成果:

平均BMI为41.2±9.3 kg/m2,平均身体脂肪百分比为43.4±7.1%.
96%的参与者表现出胰岛素抵抗.
自由甲状腺素 (FT4) 与年龄,禁食葡萄糖,胰岛素血症,胆固醇和高密度胆固醇有显著的相关性;TSH与心脏代谢参数或身体脂肪没有相关性.

结论:

在这个肥胖女性群体中,自由甲状腺素 (FT4) 与心脏代谢风险参数的关联比TSH更强.
这些发现表明,FT4可能是肥胖中代谢障碍的更相关标志物.
需要进一步的研究来阐明FT4在与肥胖相关的代谢并发症中的特定作用.

更多相关视频

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study

Published on: November 21, 2025

相关概念视频

Obesity

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

Hyperthyroidism I: Introduction

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...

Hyperthyroidism II: Pathophysiology

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...

Hypothyroidism II: Pathophysiology

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...